# A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

> **NCT06313996** · PHASE3 · WITHDRAWN · sponsor: **Juno Therapeutics, Inc., a Bristol-Myers Squibb Company**

## Conditions studied

- Relapsed or Refractory Follicular Lymphoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Rituximab
- **DRUG:** Prednisone
- **DRUG:** Bendamustine
- **DRUG:** Lenalidomide
- **DRUG:** Fludarabine
- **DRUG:** Liso-cel

## Key facts

- **NCT ID:** NCT06313996
- **Lead sponsor:** Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-03-29
- **Primary completion:** 2031-10-16
- **Final completion:** 2031-10-16
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Replaced with another clinical trial.
- **Last updated:** 2026-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06313996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06313996, "A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06313996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*